Switch theme
Sign up to access all valuation multiples
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
2009
49
LTM Revenue $2.6M
LTM EBITDA -$17.3M
$49.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Insight Molecular has a last 12-month revenue (LTM) of $2.6M and a last 12-month EBITDA of -$17.3M.
In the most recent fiscal year, Insight Molecular achieved revenue of $1.9M and an EBITDA of -$59.0M.
Insight Molecular expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Insight Molecular valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6M | XXX | $1.9M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | $0.7M | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | -$17.3M | XXX | -$59.0M | XXX | XXX | XXX |
| EBITDA Margin | -677% | XXX | -3137% | XXX | XXX | XXX |
| EBIT | -$40.1M | XXX | -$23.2M | XXX | XXX | XXX |
| EBIT Margin | -1567% | XXX | -1236% | XXX | XXX | XXX |
| Net Profit | -$40.5M | XXX | -$60.7M | XXX | XXX | XXX |
| Net Margin | -1585% | XXX | -3225% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Insight Molecular's stock price is $3.
Insight Molecular has current market cap of $77.2M, and EV of $49.7M.
See Insight Molecular trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49.7M | $77.2M | XXX | XXX | XXX | XXX | $-2.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Insight Molecular has market cap of $77.2M and EV of $49.7M.
Insight Molecular's trades at 26.4x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Insight Molecular's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Insight Molecular has a P/E ratio of -1.9x.
See valuation multiples for Insight Molecular and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $77.2M | XXX | $77.2M | XXX | XXX | XXX |
| EV (current) | $49.7M | XXX | $49.7M | XXX | XXX | XXX |
| EV/Revenue | 19.4x | XXX | 26.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.9x | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | 39.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInsight Molecular's last 12 month revenue growth is 50%
Insight Molecular's revenue per employee in the last FY averaged $38K, while opex per employee averaged $0.5M for the same period.
Insight Molecular's rule of 40 is -1489% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Insight Molecular's rule of X is -553% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Insight Molecular and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 50% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Margin | -677% | XXX | -3137% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1489% | XXX | -3088% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -553% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 523% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1275% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Insight Molecular acquired XXX companies to date.
Last acquisition by Insight Molecular was XXXXXXXX, XXXXX XXXXX XXXXXX . Insight Molecular acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Insight Molecular founded? | Insight Molecular was founded in 2009. |
| Where is Insight Molecular headquartered? | Insight Molecular is headquartered in United States of America. |
| How many employees does Insight Molecular have? | As of today, Insight Molecular has 49 employees. |
| Who is the CEO of Insight Molecular? | Insight Molecular's CEO is Mr. Joshua Riggs. |
| Is Insight Molecular publicy listed? | Yes, Insight Molecular is a public company listed on NAS. |
| What is the stock symbol of Insight Molecular? | Insight Molecular trades under IMDX ticker. |
| When did Insight Molecular go public? | Insight Molecular went public in 2015. |
| Who are competitors of Insight Molecular? | Similar companies to Insight Molecular include e.g. AnteoTech, Proteomics International, Biohit, Genomictree. |
| What is the current market cap of Insight Molecular? | Insight Molecular's current market cap is $77.2M |
| What is the current revenue of Insight Molecular? | Insight Molecular's last 12 months revenue is $2.6M. |
| What is the current revenue growth of Insight Molecular? | Insight Molecular revenue growth (NTM/LTM) is 50%. |
| What is the current EV/Revenue multiple of Insight Molecular? | Current revenue multiple of Insight Molecular is 19.4x. |
| Is Insight Molecular profitable? | Yes, Insight Molecular is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Insight Molecular? | Insight Molecular's last 12 months EBITDA is -$17.3M. |
| What is Insight Molecular's EBITDA margin? | Insight Molecular's last 12 months EBITDA margin is -677%. |
| What is the current EV/EBITDA multiple of Insight Molecular? | Current EBITDA multiple of Insight Molecular is -2.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
